Eli Lilly Bets Big on Weight-Loss Pill With $550 Million Inventory Stockpile
(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...
Becker's Spine Review2h
How weight loss medications are reshaping orthopedics
While some orthopedic and spine surgeons are divided on how medications used for weight loss, including Ozempic and Wegovy, will shape the field, it is undeniable that the drugs are playing an ...
Lilly's Chief Scientific Officer has big plans for the next generation of weight loss drugs
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Factbox-Fat, not muscle: drugmakers in race for next weight-loss breakthrough
Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...
Ozempic, Wegovy coverage demand adds to employer health-insurance costs
Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...
Online weight loss program is effective way to reach rural populations, study shows
People living in rural areas are at greater risk for obesity than the general population, and they often have limited access ...